Gene Polymorphism in Tinea Versicolor

Detection of IL1-7A and IL-17F Gene Polymorphism in Pityriasis Versicolor and Its Relation to Susceptibility to Infections.

Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 A and IL17 F.

In addition , serum samples from patients and controls will be tested for 25(OH)2 D3

Study Overview

• Status: Recruiting
• Conditions: Recurrent Pityriasis Versicolor

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

• Study Contact: Name: Rana Hilal, MD; Phone Number: +20 01001488869; Email: rana.hilal@kasralainy.edu.eg

Study Locations

• Egypt
  • El Manial
    • Cairo, El Manial, Egypt, 11956
      • Recruiting
      • Kasr Al Ainy Hospital, Cairo university
      • Contact: Rana Hilal, MD; Phone Number: +20 01001488869; Email: rana.hilal@kasralainy.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with history of disseminated TV, with 2 or more episodes of TV per year.

Description

Inclusion Criteria:

• - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
• Patients of both genders.
• Age ≥18 years old.

Exclusion Criteria:

• - Patients with other cutaneous diseases.
• Patient's having dandruff (scaly scalp) even if not symptomatizing.
• Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
• Patients with autoimmune diseases.
• Patients with immunodeficiency diseases.
• Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Patients with recurrent pityriasis versicolor
Healthy age and sex-matched controls

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IL 17A gene polymorphism	IL 17A	6months-1 year
IL 17 F gene polymorphism	IL 17 F	6months-1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vitamin D	Serum 25(OH)2 D3	6months-1 year

Collaborators and Investigators

• Sponsor: Kasr El Aini Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2019
• Primary Completion (Anticipated): June 1, 2021
• Study Completion (Anticipated): November 1, 2021

Study Registration Dates

• First Submitted: February 21, 2021
• First Submitted That Met QC Criteria: February 21, 2021
• First Posted (Actual): February 25, 2021

Study Record Updates

• Last Update Posted (Actual): April 26, 2021
• Last Update Submitted That Met QC Criteria: April 22, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Bacterial Infections and Mycoses; Skin Diseases, Infectious; Skin Diseases, Papulosquamous; Mycoses; Dermatomycoses; Tinea Versicolor; Pityriasis
• Other Study ID Numbers: PolymorphismTV

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No